Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy

BACKGROUND: Prognostic studies of insulin-like growth factor-1 receptor(IGF-1R) inhibitors in cancer therapy had promising results in infratests, which exhibited that IGF-1R signalling was crucial in cancer cells growth. However, the conclusion of later clinical trials revealed a dim future for IGF-...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Qu, Xiao, Wu, Zhinan, Dong, Wei, Zhang, Tiehong, Wang, Liguang, Pang, Zhaofei, Ma, Wei, Du, Jiajun
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5438747/
https://ncbi.nlm.nih.gov/pubmed/28427155
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15704
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы